Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Gerpinnes – page 24

599 clinical trials in Gerpinnes, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gerpinnes at a glance
599
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

599 trials in Gerpinnes

Open in trial search

Fallopian tube cancer+1

Not yet recruiting

Study of Mirvetuximab Soravtansine and Bevacizumab for Maintenance in Adults with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Transitional cell carcinoma

Not yet recruiting

Study of Disitamab Vedotin and Pembrolizumab for Patients with Advanced or Metastatic Urothelial Cancer Expressing HER2

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Disitamab Vedotin
  • Sponsor:Seagen Inc.

Colitis ulcerative

Not yet recruiting

Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Colitis ulcerative

Not yet recruiting

Study on the Effectiveness of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Malignant melanoma

Not yet recruiting

Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Melanoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.

Acute myeloid leukaemia

Not yet recruiting

Study on the Safety of Ivosidenib and Azacitidine for Adults with Newly Diagnosed IDH1m Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Servier Affaires Medicales

Pneumonia

Not yet recruiting

Study on CAL02 and Sodium Chloride for Patients with Severe Community-Acquired Bacterial Pneumonia

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cholesterol
  • Sponsor:Eagle Pharmaceuticals Inc.

Pneumonia

Not yet recruiting

Study of Baricitinib for Treating Hospital-Acquired Pneumonia in Critically Ill Patients with a Proinflammatory Profile

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Colitis ulcerative

Not recruiting

Evaluation of Long-Term Efficacy and Safety of Obefazimod as Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Gerpinnes

What the registry says about research in the country

01 Dermatology Research

Innovative clinical studies focusing on prurigo nodularis and hidradenitis suppurativa, evaluating novel therapeutic approaches for chronic skin conditions.

  • Itch and skin lesion management
  • Inflammatory skin disorders
  • Treatment-resistant conditions

Research aims to provide relief for patients with moderate to severe symptoms who haven't responded to conventional treatments.

02 Oncology Studies

Comprehensive research targeting various forms of gynecological cancers, including innovative treatments for ovarian, fallopian tube, and endometrial cancers.

  • Recurrent ovarian cancer therapy
  • Combined immunotherapy approaches
  • MUC16+ cancer treatments

Investigation of novel combination therapies to improve outcomes in recurrent cancers.

03 Emergency Medicine

Ground-breaking research in severe burn treatment and critical care, examining high-dose vitamin C therapy for life-threatening thermal injuries.

  • Organ dysfunction prevention
  • Burn trauma management
  • Critical care interventions

Studies focus on reducing mortality and improving outcomes in severely burned patients through innovative therapeutic approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.